These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 23486687

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [A molecular classification system for anaplastic glioma].
    Jiang HH, Ren XH, Zhang Z, Lin S.
    Zhonghua Wai Ke Za Zhi; 2013 Dec; 51(12):1104-9. PubMed ID: 24499721
    [Abstract] [Full Text] [Related]

  • 4. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
    Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M, Yamaguchi S, Sasayama T, Tanaka S, Higuchi F, Iuchi T, Saito K, Kanamori M, Matsuda KI, Miyake Y, Tamura K, Tamai S, Nakamura T, Uda T, Okita Y, Fukai J, Sakamoto D, Hattori Y, Pareira ES, Hatae R, Ishi Y, Miyakita Y, Tanaka K, Takayanagi S, Otani R, Sakaida T, Kobayashi K, Saito R, Kurozumi K, Shofuda T, Nonaka M, Suzuki H, Shibuya M, Komori T, Sasaki H, Mizoguchi M, Kishima H, Nakada M, Sonoda Y, Tominaga T, Nagane M, Nishikawa R, Kanemura Y, Kuchiba A, Narita Y, Ichimura K.
    Acta Neuropathol Commun; 2020 Nov 23; 8(1):201. PubMed ID: 33228806
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T.
    Neuro Oncol; 2012 Jan 23; 14(1):109-16. PubMed ID: 22039037
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
    Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, Chicoine MR, Dacey RG, Rich KM, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.
    Int J Radiat Oncol Biol Phys; 2015 Feb 01; 91(2):268-76. PubMed ID: 25636755
    [Abstract] [Full Text] [Related]

  • 9. Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
    McNamara MG, Jiang H, Lim-Fat MJ, Sahebjam S, Kiehl TR, Karamchandani J, Coire C, Chung C, Millar BA, Laperriere N, Mason WP.
    Can J Neurol Sci; 2017 May 01; 44(3):288-294. PubMed ID: 28488951
    [Abstract] [Full Text] [Related]

  • 10. Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma.
    Khan KA, Abbasi AN, Ali N.
    J Coll Physicians Surg Pak; 2014 Dec 01; 24(12):935-9. PubMed ID: 25523732
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
    Gousias K, Niehusmann P, Gielen G, Simon M, Boström J.
    J Clin Neurosci; 2014 Oct 01; 21(10):1719-24. PubMed ID: 24929863
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
    Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ.
    Neuro Oncol; 2009 Dec 01; 11(6):737-46. PubMed ID: 19224764
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.
    Clin Cancer Res; 2010 Mar 01; 16(5):1597-604. PubMed ID: 20160062
    [Abstract] [Full Text] [Related]

  • 20. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.
    Suchorska B, Giese A, Biczok A, Unterrainer M, Weller M, Drexler M, Bartenstein P, Schüller U, Tonn JC, Albert NL.
    Neuro Oncol; 2018 Jan 22; 20(2):279-288. PubMed ID: 29016996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.